新型冠状病毒肺炎合并肥胖症的评估与治疗策略

Evaluation and Treatment of Coronavirus Disease 2019 with Obesity

  • 摘要: 新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)已成为危及全球的传染性疾病,重症患者死亡风险极高。临床研究显示,肥胖症是COVID-19患者发生重症及死亡的独立危险因素。对于合并肥胖症的COVID-19患者,应尽早评估肥胖相关合并症,并在营养、气道管理、抗凝、合并症控制等方面采取更积极的干预措施,以改善预后。

     

    Abstract: The pandemic of coronavirus disease 2019 (COVID-19) has spread worldwide and the mortality is high in severe COVID-19 patients. Clinical studies suggested that obesity is an independent risk factor for severe and dead cases of COVID-19. For COVID-19 patients with obesity, early evaluation of obesity-related comorbidities and aggressive treatments, including diet control, airway management, anticoagulant thromboprophylaxis, and management of comorbidities, are encouraged to improve their prognosis.

     

/

返回文章
返回